r

Clinical Trials- Head/Neck

DISEASE SITE  TITLE  PHASE  CONTACT LOCATION 
Head/Neck A Randomized, Double-Blind, Placebo-Controlled, Phase III Study to Evaluate the Efficacy and Safety of Afatinib (BIBW 2992) as Adjuvant Therapy After Chemo- Radiotherapy in Primary Unresected Patients with Stage III, IVa, Ivb Loco-Regionally Advanced Head and Neck Squamous Cell Carcinoma (BIPI 1200.131)  III Marlene Watson RN
marlene.watson@nmhs.org
402-354-5831
Nebraska Methodist Hospital
Omaha, NE
Head/Neck

Randomized Phase II/III Trial of Surgery and Postoperative Radiation Delivered With Concurrent Cisplatin Versus Docetaxel Versus Docetaxel and Cetuximab for High-Risk Squamous (RTOG 1016)

 

 II/III Marlene Watson RN
marlene.watson@nmhs.org
402-354-5831
Nebraska Methodist Hospital
Omaha, NE
 Head/Neck Phase III Trial of Radiotherapy Plus Cetuximab versus Chemoradiotherapy in HPV-Associated Oropharynx Cancerus Cell Cancer of the Head and Neck (RTOG 1216)  III Marlene Watson RN
marlene.watson@nmhs.org
402-354-5831
 Nebraska Methodist Hospital
Omaha, NE
Head/Neck  A Phase III Study of Postoperative Radiation Therapy (IMRT) +/- Cetuximab for Locally-Advanced Resected Head and Neck Cancer (RTOG 0920)  III

Marlene Watson RN
marlene.watson@nmhs.org
402-354-5831 

and

Saint Elizabeth – Michelle Broman – mbroman@stez.org

Nebraska Methodist Hospital
Omaha, NE

and at

Saint Elizabeth Cancer Center, Lincoln, NE

Head/Neck A Randomized, Open-Label, Phase III Study to Evaluate the Efficacy and Safety of Oral Afatinib (BIBW 2992) Versus Intravenous Methotrexate in Patients with Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma
(BIPI 1200.43)
 III Marlene Watson RN
marlene.watson@nmhs.org
402-354-5831
Nebraska Methodist Hospital
Omaha, NE
Salivary Gland A Randomized Phase II Study of Adjuvant Concurrent Radiation and
Chemotherapy Versus Radiation Alone in Resected High-Risk Malignant Salivary Gland Tumors (RTOG 1008)
 II Marlene Watson RN
marlene.watson@nmhs.org
402-354-5831
Nebraska Methodist Hospital
Omaha, NE
 Laryngeal TALC Study MBS Protocol: Observational Study of Swallowing Function After Treatment of Advanced Laryngeal Cancer   Marlene Watson RN
marlene.watson@nmhs.org
402-354-5831
Nebraska Methodist Hospital
Omaha, NE
 Thyroid Development and Implementation of the Thyroid Cancer Collaborative Registry (TCCR) (UNMC Registry 463-07)   Marlene Watson RN
marlene.watson@nmhs.org
402-354-5831
 Nebraska Methodist Hospital
Omaha, NE
 Head/Neck  "A Phase III Randomized Trial of Chemotherapy With or Without Bevacizumab in Patients with Recurrent
or Metastatic Head and Neck Cancer (E1305)" 
 III

 Marcia Grafe                    402-483-2827 mgrafe@lmep.com and

Good Samaritan – Michaela Sherbeck - michaelasherbeck@catholichealth.net

 Lincoln Medical Education Partnership Lincoln, NE

and at

Good Samaritan Cancer Center, Kearney, NE

 Head/Neck  A Phase III Randomized Trial of Chemotherapy With or Without Bevacizumab in Patients with Recurrent or Metastatic Head and Neck Cancer (E1305)  III

 Natasha Wilson, nwilson@mvcc.cc

 402-991-8070 x203

 Missouri Valley Cancer Consortium, Omaha, NE
 Head/Neck  A Phase III Study of Postoperative Radiation therapy (IMRT) +/- Cetuximab for Locally-Advanced Resected Head and Neck Cancer  III  

Deborah Meyer, RN, BGS

 (402) 559-6941

dmeyerk@unmc.edu

or Amy Filler-Kaz
 The Nebraska Medical Center, Omaha, NE
 Head/Neck  ARAR0331 - Treatment of Childhood Nasopharyngeal Carcinoma with neoadjuvant Chemotherapy and Concomitant Chemotherapy (Children's 603-1108/UNMC 078-10)    

Deborah Meyer, RN, BGS

 (402) 559-6941

dmeyerk@unmc.edu

or Tamra Olson
 The Nebraska Medical Center, Omaha, NE
 Head/Neck  RTOG 1016, Phase III Trial of Radiotherapy Plus Cetuximab versus Chemoradiotherapy in HPV-Associated Oropharynx Cancer  III  

Deborah Meyer, RN, BGS

 (402) 559-6941

dmeyerk@unmc.edu

or Amy Filler- Katz
 The Nebraska Medical Center, Omaha, NE

 

 

Nebraska Oncology Society
c/o Nebraska Medical Association
Sarah Dunbar
Executive Director
233 South 13th Street Suite 1200
Lincoln, NE 68508
sarahd@nebmed.org (email)
402-474-4472 (phone)
402-474-2198 (fax)

Powered by Wild Apricot Membership Software